Flerie AB

FLERIE.ST · Health Technology · Pharmaceuticals: Major · SE

6 employees · indexpharma.com

About

InDex Pharmaceuticals Holding AB develops drugs for inflammation and cancer, including cobitolimod for ulcerative colitis. The company offers a diagnostic kit called DiBiCol, which uses PCR to monitor seven biomarkers from colonic biopsies for ulcerative colitis or Crohn’s disease. InDex Pharmaceuticals AB and InDex Diagnostics AB are its subsidiaries, with SEB Venture Capital, Industrifonden, and NeoMed Management as shareholders. The firm focuses on pharmaceutical development and immuno-modulatory sequences (DIMS) for immunological diseases. The company generates revenue through the development and commercialization of cobitolimod and DIMS-based platforms. DiBiCol diagnostic kits are sold to healthcare providers for monitoring ulcerative colitis and Crohn’s disease. SEB Venture Capital, Industrifonden, and NeoMed Management are key investors supporting the company's research and development activities. InDex Pharmaceuticals Holding AB operates as a parent company for its subsidiaries in pharmaceutical and diagnostic fields.

Annual results

Reported figures, SEK

YearRevenueNet incomeNet marginFree cash flow
20258.0M-756M-9450.0%—
2024—-228M——
202397.0M-95.0M-97.9%—
2022—-100M——
2021—-103M——

FLERIE.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Flerie AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Flerie AB (FLERIE.ST) — company profile and financials · MarketPulse